GGrantIndex
← Leaderboards

Darrell M Wilson

Stanford University

$9,493,607
Attributed
$9,493,607
Total exposure
27
Grants
19
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $1.1M · FY200518
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18

Funding mix

By agency

NIH$9,493,607 · 27

By mechanism

U01$8,477,948 · 1
M01$698,970 · 25
U10$316,689 · 1

Top collaborators

No co-investigators on record.

Most similar at Stanford University

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Trials

Research focus

Clinical TrialsInsulinClinical ResearchDiabetes MellitusHuman SubjectRandomizedPreventionPreventInsulin Dependent Diabetes MellitusAdolescentChildHuman Therapy EvaluationFundingEnrollmentGrantUnited States National Institutes Of HealthResearch PersonnelResourcesSourceComputer Retrieval Of Information On Scientific Projects DatabaseInstitutionMediatingUniversitiesDisease /Disorder Prevention /Control

Grant awards (55)

TrialNet at Stanford University$532,743
U01 · FY2018 · DK · contact PI
TrialNet at Stanford University$493,547
U01 · FY2017 · DK · contact PI
TrialNet at Stanford University$493,547
U01 · FY2016 · DK · contact PI
TrialNet at Stanford University$493,547
U01 · FY2015 · DK · contact PI
TrialNet at Stanford University$493,589
U01 · FY2014 · DK · contact PI
Type 1 Diabetes TrialNet at Stanford$15,164
U01 · FY2014 · DK · contact PI
Type 1 Diabetes TrialNet at Stanford$657,024
U01 · FY2013 · DK · contact PI
Type 1 Diabetes TrialNet at Stanford$536,530
U01 · FY2012 · DK · contact PI
Type 1 Diabetes TrialNet at Stanford$525,436
U01 · FY2011 · DK · contact PI
Type 1 Diabetes TrialNet at Stanford$553,480
U01 · FY2010 · DK · contact PI
Type 1 Diabetes TrialNet at Stanford$437,882
U01 · FY2009 · DK · contact PI
CLINICAL TRIAL: TRIALNET SCREENING TO ASSESS RISK OF TYPE 1 DIABETES$7,964
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: RITUXIMAB ON THE PROGRESSION OF TYPE 1 DIABETES IN NEW ONSET SUB$6,713
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: TYPE 1 DIABETES: CELLCEPT ALONE OR IN COMBINATION WITH DACLIZUMA$5,461
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: TRIAL OF METFORMIN IN OBESE ADOLESCENTSMETFORMIN IN OBESE ADOL$1,479
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: SHARED DIABETES TRIAL STUDIES$796
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: ORAL INSULIN IN RELATIVES AT RISK FOR TYPE I DIABETES MELLITUS$455
M01 · FY2008 · RR · contact PI
Type 1 Diabetes TrialNet at Stanford$935,273
U01 · FY2007 · DK · contact PI
TYPE 1 DIABETES: CELLCEPT ALONE OR IN COMBINATION WITH DACLIZUMAB$55,003
M01 · FY2007 · RR · contact PI
TRIALNET SCREENING TO ASSESS RISK OF TYPE 1 DIABETES$33,353
M01 · FY2007 · RR · contact PI
TRIAL OF METFORMIN IN OBESE ADOLESCENTS$21,065
M01 · FY2007 · RR · contact PI
SHARED DIABETES TRIAL STUDIES$4,682
M01 · FY2007 · RR · contact PI
RECENT ONSET TYPE-1 DIABETES MELLITUS STUDY OF USING FRESH BLOOD SAMPLES$1,171
M01 · FY2007 · RR · contact PI
EFFECTS OF RITUXIMAB ON THE PROGRESSION OF TYPE 1 DIABETES$585
M01 · FY2007 · RR · contact PI
Type I Diabetes Trialnet at Stsnford$183,093
U01 · FY2006 · DK · contact PI
METFORMIN IN OBESE ADOLESCENTS$31,134
M01 · FY2006 · RR · contact PI
IMPROVING METABOLIC ASSESSMENTS IN TYPE-1 DIABETES MELLITUS CLINICAL TRIALS$25,797
M01 · FY2006 · RR · contact PI
IMMUNOTHERAPY FOR NEW ONSET TYPE-1 DIABETES$23,128
M01 · FY2006 · RR · contact PI
TRIALNET SCREENING TO ASSESS RISK OF TYPE-1 DIABETES$14,233
M01 · FY2006 · RR · contact PI
BLOOD SAMPLES FROM SUBJECTS WITH RECENT ONSET TYPE-1 DIABETES MELLITUS$8,896
M01 · FY2006 · RR · contact PI
SHARED DIABETES TRIAL STUDIES$8,006
M01 · FY2006 · RR · contact PI
Type I Diabetes Trialnet at Stsnford$771,086
U01 · FY2005 · DK
Type I Diabetes Trialnet at Stsnford$72,564
U01 · FY2005 · DK
METFORMIN IN OBESE ADOLESCENTS$18,711
M01 · FY2005 · RR
SHARED DIABETES TRIAL STUDIES$10,023
M01 · FY2005 · RR
IMMUNOTHERAPY FOR NEW ONSET TYPE 1 DIABETES$5,680
M01 · FY2005 · RR
TRIALNET SCREENING TO ASSESS RISK OF TYPE 1 DIABETES$1,671
M01 · FY2005 · RR
A DIABETES PREVENTION TRIAL FOR TYPE I DIABETES [DPT-1]$334
M01 · FY2005 · RR
Type I Diabetes Trialnet at Stsnford$333,926
U01 · FY2004 · DK
Multicenter Intervention Trial to Prevent IDD$6,519
M01 · FY2004 · RR
A Multi-center, Randomized, Placebo-Controlled$1,185
M01 · FY2004 · RR
Shared Diabetes Trial Studies$296
M01 · FY2004 · RR
Type I Diabetes Trialnet at Stsnford$322,200
U01 · FY2003 · DK
Type I Diabetes Trialnet at Stsnford$321,767
U01 · FY2002 · DK
Near-Continuous Glucose Monitoring in Pediatrics$316,689
U10 · FY2001 · HD
Type I Diabetes Trialnet at Stanford$305,550
U01 · FY2001 · DK
INTENSIVE INSULIN REGIMEN FOR TYPE I DIABETES MELLITUS$134,676
M01 · FY2001 · RR
MULTICENTER INTERVENTION TRIAL TO PREVENT INSULIN-DEPENDENT DIABETES MELLITUS$134,676
M01 · FY2001 · RR
IMPROVED MONITORING OF GNRH ANALOG THERAPY$134,676
M01 · FY2001 · RR
MULTICENTER INTERVENTION TRIAL TO PREVENT INSULIN-DEPENDENT DIABETES MELLITUS$0
M01 · FY2001 · RR
IMPROVED MONITORING OF GNRH ANALOG THERAPY$0
M01 · FY2001 · RR
INTENSIVE INSULIN REGIMEN FOR TYPE I DIABETES MELLITUS$0
M01 · FY2001 · RR
MULTICENTER INTERVENTION TRIAL TO PREVENT INSULIN-DEPENDENT DIABETES MELLITUS$602
M01 · FY2000 · RR
IMPROVED MONITORING OF GNRH ANALOG THERAPY$0
M01 · FY2000 · RR
INTENSIVE INSULIN REGIMEN FOR TYPE I DIABETES MELLITUS$0
M01 · FY2000 · RR